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The spread of pandemic Inﬂuenza A (H1N1-2009) was believed to have been attenuated by the eﬀectiveness of worldwide
vaccination initiatives. Despite the immunogenicity of a safe vaccine, we report a case of vaccine failure resulting in catastrophic
inﬂuenza-associated respiratory failure.
Pandemic Inﬂuenza A (H1N1-2009) was not only distin-
guished by a predilection towards relatively young and
otherwise healthy patients, but was also associated with a
high incidence of catastrophic respiratory failure requiring
extracorporeal membrane oxygenation (ECMO) [1, 2]. The
rapid development and distribution of an eﬀective vaccine
was attributed to attenuating what was already a pandemic
outbreak. Nevertheless, even in 2011, H1N1-2009 continues
to be a challenging clinical and epidemiologic problem.
H1N1-2009 vaccination was determined to be >95%
eﬀective within 3 weeks in otherwise healthy adults [3, 4].
While serious infections in vaccinated patients have been
reported [5], many of these patients have risk factors for
vaccination failure—such as chronic institutionalization or
disabled and debilitated patients who may lack a functional
immune system—and the “severity” of illness is debatable.
We present a case of a previously healthy male, with docu-
mented vaccination and a suﬃcient lag time to develop an
appropriate antibody response, in which severe H1N1-2009-
associated respiratory failure developed requiring ECMO.
Our patient was a 53-year old previously healthy,
nonsmoker with no reported unusual recent exposures,
male who presented to an outside hospital with severe
respiratory distress. He was started on empiric broad-
spectrum antibiotics and oseltamivir phosphate (150mg
PO BID, Tamiﬂu, Genentech, Inc., San Francisco, Calif,
USA) and Methylprednisolone (60mg intravenous, Q6H
for 3 days). Initial bacterial blood and respiratory cultures
were negative, but had a positive nasal swab for Inﬂuenza
H1N1. Initial chest X-ray showed severe diﬀuse pulmonary
inﬁltrates and edema consistent with adult respiratory dis-
tress syndrome (ARDS, Figure 1). Five days later, due to
failure of maximal mechanical ventilation and worsening
hypoxemia with hypercarbia he was placed on percutaneous
veno-veno ECMO and transferred to our Institution. Upon
arrival, bacterial and fungal blood, urine, and respiratory
cultures from a bronchial alveolar lavage were obtained
and were negative. Real-time polymerase chain reaction
assay was positive for H1N1-2009. Other viral cultures,
including HIV-1/-2 and a hepatitis panel, were negative.
A transthoracic echocardiogram was unremarkable. Over
several days, antibiotic therapy was deescalated, and he
completed a 10-day course of oseltamivir.
After 7 days of ECMO support, he was successfully
weaned and decannulated. His ventilator requirements
slowly improved, and despite an Enterobacter aerogenes
ventilator-associated pneumonia that developed post-
ECMO decannulation, the remainder of his hospital course
was unremarkable. He was discharged for rehabilitation 22
days after ECMO decannulation (hospital day 31).
At followup, 4 months following-discharge, he was doing
well, repeat chest X-ray showed no evidence of acute or
chronic disease, and pulmonary function testing showed
normal spirometry, a mild restrictive ventilatory defect, a
mildly impaired diﬀusing capacity (23.6ml/min/mmHg,
74% predicted), and a normal 6-minute walk (515 meters,2 Case Reports in Infectious Diseases
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Figure 1: Admission chest X-ray showing severe bilateral diﬀuse
pulmonary inﬁltrates.
normal: 365 meters). In discussion with the patient, he
recalled having been vaccinated against “the ﬂu”. Following
appropriate release of medical records, it was conﬁrmed
that 2 months prior to the onset of symptoms he received
0.5ml of inactivated trivalent inﬂuenza vaccine in the left
deltoid (Fluzone, Sanoﬁ-Pasteur Inc., Swiftwater, Pa, USA)
[6]. Vaccination was provided by a local Pharmacy run
vaccination clinic with established policies and procedures
conforming to State and Federal regulations regarding the
storage and administration of vaccines. No postvaccination
problems were reported.
Inﬂuenza H1N1-2009 was a formidable challenge world-
wide during 2009 in terms of severity of illness and ease of
transmission, particularly in otherwise young and healthy
patients [7]. The Australian experience estimated 1.6–2.6
cases per million required ECMO following infection with
H1N1. In the 68 patients who required ECMO the mortality
was 21%—a rate much greater than expected with recent
seasonal Inﬂuenza outbreaks [2].
Large-scale vaccination eﬀorts were undertaken to mini-
mize the spread and impact of the evolving pandemic. While
the immunogenicity of the vaccine has been documented,
the incidence of seroconversion is variable. In one study,
only 75% of adults seroconverted [8] while another study
demonstrated a 95% seroconversation rate within 21 days
in those adults who received a single 15ug dose of a
trivalent, unadjuvanted, inactivated, split-virus vaccine [4].
Regardless, given inherent variability in antigenicities and
immune responses, with such a large population at risk,
even a small percentage of vaccine failure can have a sig-
niﬁcantepidemiologicimpact.Furthermore,consideringthe
virulence of H1N1-2009 the risk of developing catastrophic
respiratory failure requiring high-intensity ventilator or even
ECMO support is not negligible.
Conclusions. Our recent case, in a patient who presented
in early 2011, illustrates several concerns. First, despite less
worldwide emphasis, seasonal ﬂu, and in particular H1N1,
remains a signiﬁcant and potentially deadly problem in
relatively young and healthy patients. More importantly,
clinicians who encounter patients with severe “inﬂuenza like
illnesses” even with documented vaccine histories should
strongly be considered for appropriate antiviral therapies.
In severe cases, ECMO should be considered and can be
life saving in those patient failing conventional ventilator
therapies [9].
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